BRPI0411823A - derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico - Google Patents
derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlicoInfo
- Publication number
- BRPI0411823A BRPI0411823A BRPI0411823-5A BRPI0411823A BRPI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A BR PI0411823 A BRPI0411823 A BR PI0411823A
- Authority
- BR
- Brazil
- Prior art keywords
- hexane
- amino
- ester derivative
- hydrogen atom
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Furan Compounds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
Abstract
"DERIVADO DE éSTER 2-AMINO-BICICLO¢3.1.0!-HEXANO-2,6-DICARBOXìLICO". A presente invenção refere-se a um medicamento eficaz para o tratamento e prevenção de distúrbios psiquiátricos tais como esquizofrenia, ansiedade e suas doenças relacionadas, depressão, distúrbio bipolar e epilepsia. O medicamento antagoniza a ação dos receptores de glutamato metabotrópico do grupo II e apresenta atividade elevada na administração oral. Um derivado de éster 2-amino-biciclo ¢3.1.0! hexano-2,6-dicarboxílico representado pela fórmula ¢I! ¢em que R¬ 1¬ e R¬ 2¬ são idênticos ou diferentes, e cada um representa um átomo de hidrogênio, um grupo de C~ 1-10~alquila ou similar; X representa um átomo de hidrogênio ou um átomo de flúor; Y representa -OCHR¬ 3¬R¬ 4¬ ou similar (em que R¬ 3¬ e R¬ 4¬ são idênticos ou diferentes, e cada um representa um átomo de hidrogênio, um grupo de C~ 1-10~alquila ou similar; e n representa o número inteiro 1 ou 2)!, um sal farmaceuticamente aceitável deste ou um hidrato do mesmo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003181930 | 2003-06-26 | ||
| JP2003373511 | 2003-10-31 | ||
| JP2004128663 | 2004-04-23 | ||
| PCT/JP2004/009398 WO2005000791A1 (ja) | 2003-06-26 | 2004-06-25 | ２－アミノ－ビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸エステル誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0411823A true BRPI0411823A (pt) | 2006-08-08 |
Family
ID=33556154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0411823-5A BRPI0411823A (pt) | 2003-06-26 | 2004-06-25 | derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US7960579B2 (pt) |
| EP (3) | EP2287147B1 (pt) |
| JP (1) | JP4792971B2 (pt) |
| KR (1) | KR101071507B1 (pt) |
| AT (1) | ATE487690T1 (pt) |
| AU (2) | AU2004252017B2 (pt) |
| BR (1) | BRPI0411823A (pt) |
| CA (1) | CA2530706C (pt) |
| CY (1) | CY1110997T1 (pt) |
| DE (1) | DE602004030007D1 (pt) |
| DK (2) | DK2123630T3 (pt) |
| ES (1) | ES2394175T3 (pt) |
| HR (1) | HRP20100619T1 (pt) |
| MX (1) | MXPA05013740A (pt) |
| NO (1) | NO335004B1 (pt) |
| NZ (2) | NZ580554A (pt) |
| PL (1) | PL1637517T3 (pt) |
| PT (1) | PT1637517E (pt) |
| SI (1) | SI1637517T1 (pt) |
| WO (1) | WO2005000791A1 (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2530706C (en) * | 2003-06-26 | 2012-11-27 | Taisho Pharmaceutical Co., Ltd. | 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative |
| TW201129700A (en) | 2009-11-18 | 2011-09-01 | Taisho Pharmaceutical Co Ltd | Method for producing optically active bicyclo [310] hexane derivative using oxygen |
| US8642777B2 (en) | 2009-11-19 | 2014-02-04 | Taisho Pharmaceutical Co., Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| CN103209954B (zh) * | 2010-11-18 | 2015-09-02 | 伊莱利利公司 | 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物 |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| AR089718A1 (es) | 2012-02-01 | 2014-09-10 | Lilly Co Eli | AGONISTAS DE mGlu2/3 |
| JP5983713B2 (ja) * | 2013-11-29 | 2016-09-06 | 大正製薬株式会社 | 含フッ素アミノ酸のプロドラッグを含有する医薬 |
| FR3026843B1 (fr) * | 2014-10-03 | 2016-11-18 | Univ Pierre Et Marie Curie Paris 6 | Procede de caracterisation du mecanisme de fissuration d'un materiau a partir de sa surface de rupture |
| EP3445743B1 (en) | 2016-04-18 | 2021-08-04 | Taisho Pharmaceutical Co., Ltd. | Prodrug of amino acid derivative |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| KR101877672B1 (ko) | 2017-04-03 | 2018-07-11 | 엘에스산전 주식회사 | Ａｄ컨버터 |
| WO2020018670A1 (en) * | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US11501618B1 (en) * | 2018-10-19 | 2022-11-15 | Amazon Technologies, Inc. | Security device with user-configurable motion detection settings |
| CN116444470B (zh) * | 2023-03-29 | 2025-04-04 | 河南中烟工业有限责任公司 | 一种二羧酸二ddmp酯类化合物、制备方法及应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750566A (en) * | 1994-08-12 | 1998-05-12 | Eli Lilly And Company | Synthetic excitatory amino acids |
| GB9605429D0 (en) | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
| ZA983930B (en) | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | ６−フルオロビシクロ［３．１．０］ヘキサン誘導体 |
| ATE269293T1 (de) | 1998-08-31 | 2004-07-15 | Taisho Pharmaceutical Co Ltd | 6-fluoro(3.1.0)hexan-derivate |
| CH694053A5 (de) * | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
| AU6785401A (en) * | 2000-06-28 | 2002-01-08 | Taisho Pharmaceutical Co Ltd | Novel dicarboxylic acid derivatives |
| EP1370519A1 (en) * | 2001-02-22 | 2003-12-17 | Eli Lilly And Company | Synthetic excitatory amino acids |
| CA2471642C (en) | 2001-12-27 | 2011-05-24 | Taisho Pharmaceutical Co., Ltd. | 6-fluorobicyclo[3.1.0]hexane derivatives |
| JP4984529B2 (ja) | 2003-06-26 | 2012-07-25 | 大正製薬株式会社 | ２−アミノビシクロ［３．１．０］ヘキサン−２，６−ジカルボン酸誘導体 |
| JP2007063129A (ja) | 2003-06-26 | 2007-03-15 | Taisho Pharmaceut Co Ltd | ２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体 |
| CA2530706C (en) * | 2003-06-26 | 2012-11-27 | Taisho Pharmaceutical Co., Ltd. | 2-amino-bicyclo[3.1.0] hexane-2,6-dicarboxylic ester derivative |
-
2004
- 2004-06-25 CA CA2530706A patent/CA2530706C/en not_active Expired - Fee Related
- 2004-06-25 PT PT04746867T patent/PT1637517E/pt unknown
- 2004-06-25 DK DK09166100.9T patent/DK2123630T3/da active
- 2004-06-25 ES ES09166100T patent/ES2394175T3/es not_active Expired - Lifetime
- 2004-06-25 PL PL04746867T patent/PL1637517T3/pl unknown
- 2004-06-25 MX MXPA05013740A patent/MXPA05013740A/es active IP Right Grant
- 2004-06-25 EP EP10181930.8A patent/EP2287147B1/en not_active Expired - Lifetime
- 2004-06-25 NZ NZ580554A patent/NZ580554A/en not_active IP Right Cessation
- 2004-06-25 AU AU2004252017A patent/AU2004252017B2/en not_active Ceased
- 2004-06-25 HR HR20100619T patent/HRP20100619T1/hr unknown
- 2004-06-25 BR BRPI0411823-5A patent/BRPI0411823A/pt not_active IP Right Cessation
- 2004-06-25 DE DE602004030007T patent/DE602004030007D1/de not_active Expired - Lifetime
- 2004-06-25 DK DK04746867.3T patent/DK1637517T3/da active
- 2004-06-25 JP JP2005511127A patent/JP4792971B2/ja not_active Expired - Lifetime
- 2004-06-25 AT AT04746867T patent/ATE487690T1/de active
- 2004-06-25 NZ NZ544131A patent/NZ544131A/xx not_active IP Right Cessation
- 2004-06-25 EP EP09166100A patent/EP2123630B1/en not_active Expired - Lifetime
- 2004-06-25 WO PCT/JP2004/009398 patent/WO2005000791A1/ja not_active Ceased
- 2004-06-25 SI SI200431569T patent/SI1637517T1/sl unknown
- 2004-06-25 US US10/562,018 patent/US7960579B2/en not_active Expired - Fee Related
- 2004-06-25 EP EP04746867A patent/EP1637517B1/en not_active Expired - Lifetime
- 2004-06-25 KR KR1020057024818A patent/KR101071507B1/ko not_active Expired - Fee Related
-
2006
- 2006-01-26 NO NO20060428A patent/NO335004B1/no not_active IP Right Cessation
-
2009
- 2009-07-29 US US12/511,482 patent/US8039647B2/en not_active Expired - Fee Related
- 2009-09-15 AU AU2009217374A patent/AU2009217374B2/en not_active Ceased
-
2010
- 2010-07-30 US US12/847,392 patent/US8076502B2/en not_active Expired - Fee Related
- 2010-12-17 CY CY20101101160T patent/CY1110997T1/el unknown
-
2011
- 2011-09-08 US US13/227,942 patent/US8350060B2/en not_active Expired - Fee Related
- 2011-10-07 US US13/269,242 patent/US8258133B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0411823A (pt) | derivado de éster 2-amino-biciclo[3.1.0]hexano-2,6-dicarboxìlico | |
| BR0317273A (pt) | Utilizações farmacêuticas para ligandos alfa2delta | |
| BRPI0415746A (pt) | derivados de amida | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| IL188172A0 (en) | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | |
| BR0317600A (pt) | ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina | |
| AR030533A1 (es) | Compuestos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas, composicion farmaceutica, procedimiento de tratamiento intermediario | |
| BRPI0507984A (pt) | composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto | |
| BR0311494A (pt) | Novos indóis substituìdos | |
| DE69940557D1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| EP2473482B1 (en) | Methods of treating orthomyxoviral infections | |
| HUP9702241A2 (hu) | 2-Amino-indán-származékok és az ezeket tartalmazó gyógyszerkészítmények | |
| BR9811093A (pt) | Piridinas substituìdas com 2-amino-6-(4-fenóxi 2-substituìdo) | |
| IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| BR0103210A (pt) | Derivados de azabicicloalcano e suas utilizações terapêuticas | |
| BR0317289A (pt) | Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico | |
| ATE160143T1 (de) | 2-substituierte morpholin- und thiomorpholinderivate als gaba-b antagonisten | |
| ATE302184T1 (de) | Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors | |
| BR0010961A (pt) | Composto, composição farmacêutica, e, métodos para tratar epilepsia, ataques de tontura, hipocinésia, e distúrbios cranianos, distúrbios neurodegenerativos, depressão, ansiedade, pânico, dor, distúrbios neuropatológicos e distúrbios do sono | |
| AR037711A1 (es) | Sal de acido citrico de un compuesto terapeutico y composiciones farmaceuticas que la contienen | |
| UY28119A1 (es) | Nuevos derivados que contienen fosforo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2312 DE 28-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |